FA
CRL icon

Friess Associates’s Charles River Laboratories CRL Stock Holding History

Friess Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-132,911
Closed -$19.3M – 120
2019
Q1 		$19.3M Buy
+132,911
New +$17.5M 1.42% 25

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Friess Associates's CRL Position: Q2 2019 in Review

Friess Associates sold out of Charles River Laboratories (CRL) in Q2 2019, closing a stake of 132,911 shares — an estimated $19.3M sold.

Friess Associates first reported a position in CRL in Q1 2019 and held it in 1 quarter. The position peaked at $19.3M in Q1 2019. 405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

  • Friess Associates reported no remaining Charles River Laboratories position as of Q2 2019 after selling out during the quarter.
  • Friess Associates sold 132,911 Charles River Laboratories shares in Q2 2019, an estimated $19.3M.
  • Friess Associates first reported a position in Charles River Laboratories in Q1 2019 and held it in 1 quarter.
  • Friess Associates's Charles River Laboratories position peaked at $19.3M in Q1 2019.
  • 405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Friess Associates's 13F filing for Q2 2019, filed 14 Aug 2019.